Viracta Therapeutics Stock Forecast, Price & News

+0.26 (+2.54 %)
(As of 05/7/2021 05:20 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume218,973 shs
Average Volume739,395 shs
Market Capitalization$54.33 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VIRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:VIRX
Phone858 400 8470
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Market Cap$54.33 million
Next Earnings DateN/A
OptionableNot Optionable


See More Headlines
Viracta Therapeutics logo

About Viracta Therapeutics

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff, California.


Overall MarketRank

1.58 out of 5 stars

Medical Sector

427th out of 2,042 stocks

Biotechnology Industry

28th out of 158 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Viracta Therapeutics (NASDAQ:VIRX) Frequently Asked Questions

Is Viracta Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viracta Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Viracta Therapeutics stock.
View analyst ratings for Viracta Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Viracta Therapeutics?

Wall Street analysts have given Viracta Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Viracta Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for VIRX?

4 brokers have issued 1 year price objectives for Viracta Therapeutics' stock. Their forecasts range from $18.00 to $45.00. On average, they anticipate Viracta Therapeutics' share price to reach $33.50 in the next year. This suggests a possible upside of 219.0% from the stock's current price.
View analysts' price targets for Viracta Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Viracta Therapeutics' key executives?

Viracta Therapeutics' management team includes the following people:
  • Dr. Ivor Royston, CEO, Pres & Director (Age 75, Pay $456.75k)
  • Mr. Daniel R. Chevallard, CFO, COO & Sec. (Age 41, Pay $418.25k)
  • Dr. Lisa Rojkjaer, Chief Medical Officer (Age 55, Pay $463.7k)
  • Dr. Susan Perrine M.D., Scientific Founder and Consultant
  • Dr. Ronald J. Berenson M.D., Co-Founder and Consultant (Age 69)
  • Mr. George Hillman, Co-Founder
  • Dr. Thalia Papayannopoulou M.D., Co-Founder
  • Mr. Robert M. Williams, Co-Founder (Age 66)
  • Dr. Douglas V. Faller Ph.D., M.D., Scientific Founder & Chairman of Scientific Advisory Board
  • Mr. Michael Mueller, VP of Legal Affairs & Gen. Counsel

Who are some of Viracta Therapeutics' key competitors?

What is Viracta Therapeutics' stock symbol?

Viracta Therapeutics trades on the NASDAQ under the ticker symbol "VIRX."

Who are Viracta Therapeutics' major shareholders?

Viracta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.60%) and Sowell Financial Services LLC (0.08%).

Which major investors are buying Viracta Therapeutics stock?

VIRX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., and Sowell Financial Services LLC.

How do I buy shares of Viracta Therapeutics?

Shares of VIRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viracta Therapeutics' stock price today?

One share of VIRX stock can currently be purchased for approximately $10.50.

How much money does Viracta Therapeutics make?

Viracta Therapeutics has a market capitalization of $54.33 million.

What is Viracta Therapeutics' official website?

The official website for Viracta Therapeutics is

How can I contact Viracta Therapeutics?

The company can be reached via phone at 858 400 8470.

This page was last updated on 5/9/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.